Regeneron 3-Year Results for EYLEA HD in Patients with Wet Age-related Macular Degeneration

 

Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

At three years, the vast majority of patients who switched to EYLEA HD from a fixed 2-month dosing regimen with EYLEA® (aflibercept) Injection 2 mg maintained visual and anatomic improvements while rapidly extending their dosing intervals: 79%, 43% and 16% achieved last assigned dosing intervals of ≥3, ≥4 and ≥5 months, respectively

https://www.globenewswire.com/news-release/2025/02/08/3023108/0/en/Three-Year-Results-for-EYLEA-HD-aflibercept-Injection-8-mg-in-Patients-with-Wet-Age-related-Macular-Degeneration-Demonstrate-Continued-Durable-Vision-Gains-and-Anatomic-Improvement.html